Retatrutide Half-Life & Pharmacokinetics: 6-Day Decay Curve

What Is Retatrutide's Half-Life?

The half-life of a drug is the time it takes for plasma concentration to fall by 50%. For retatrutide, that number is approximately 6 days, or 144 hours, based on the Phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine in 2023. The trial states directly: "The pharmacokinetics of retatrutide are considered dose-proportional; it has a half-life of approximately 6 days, which enables weekly administration."

Dose-proportional pharmacokinetics means the drug's concentration in your bloodstream scales linearly with your dose. Doubling the dose roughly doubles the plasma level, which is a useful property for titration planning. It also means the 6-day half-life holds across the full tested dose range of 0.5mg to 12mg, you don't see a different half-life at lower or higher doses.

The "approximately 6 days" figure is the lexicon standard and the one to use. Some sources cite "6 to 8 days," but this range comes from non-Tier-1 sources. The NEJM trial, the PMC review by Katsi et al. (2025), and the European Journal of Pharmacology paper by Abdul-Rahman et al. (2024) all confirm approximately 6 days. For a complete look at how this half-life shapes your protocol, the retatrutide dosing guide covers the titration logic in detail.

Why a 6-Day Half-Life Enables Once-Weekly Dosing

With a half-life of 6 days, a meaningful fraction of each dose is still circulating when the next injection is due. Seven days after a dose, roughly 56% has cleared, leaving about 44% of the peak still active, one half-life elapses at day 6, so day 7 sits just past the halfway mark. Across repeated weekly doses the drug accumulates to a steady state, so trough levels hold high enough to maintain therapeutic effect, without a cliff-like drop before the next dose. This is exactly the pharmacokinetic profile a weekly medication needs.

Compare this to short-acting GLP-1 agents with half-lives of hours, which require daily or twice-daily dosing. Retatrutide's fatty-acid acylation chemistry (explained below) extends its residence in the bloodstream, making once-weekly subcutaneous injection viable. All three major weekly GLP-class agents sit in a similar half-life band, which is why all three use the same weekly injection schedule:

No head-to-head pharmacokinetic trial has directly compared these three compounds. The figures above come from separate studies with different populations and designs. For a full clinical comparison, see the retatrutide vs tirzepatide guide.

How Retatrutide Achieves Its Long Half-Life

Retatrutide's extended half-life results from fatty-acid acylation, a chemical modification that allows the molecule to bind to albumin, the most abundant protein in blood plasma. Albumin acts as a reservoir and a shield: it slows renal filtration, protects the molecule from enzymatic degradation, and releases it slowly over time. This is the same core mechanism used to extend tirzepatide and semaglutide beyond the typical GLP-1 peptide half-life of minutes to hours.

The Abdul-Rahman et al. review (European Journal of Pharmacology, 2024) notes that the albumin-binding design "supports once-weekly subcutaneous administration" and that the long half-life is a key feature of the pharmacokinetic profile. The Katsi et al. review (PMC, 2025) confirms the mean half-life of approximately 6 days in the published trial data.

How Long Does Retatrutide Stay In Your Body?

The standard pharmacokinetic rule is that 97% of a drug clears after five half-lives. With a 6-day half-life, that puts full clearance at approximately 30 days after the last dose. The drug does not disappear overnight, it follows an exponential decay curve, shedding roughly half its remaining concentration every 6 days.

Actual clearance varies by individual. Body composition, kidney function, and liver function all influence how quickly the drug processes. The 30-day figure is the mean from the published Phase 2 trial, not a guaranteed window for every person. If you need precise clearance timing before a procedure or medication switch, your doctor is the right call.

What Happens When You Stop Taking Retatrutide?

As retatrutide clears over approximately 30 days, its pharmacological effects wind down in proportion to falling drug levels. Appetite suppression fades as the drug loses its grip on GLP-1, GIP, and glucagon receptors. The enhanced energy expenditure from glucagon receptor stimulation also declines as drug levels drop.

The broader GLP-1 class literature, and the Phase 2 retatrutide data specifically, documents that weight regain is common after discontinuation. This is not a sign that the drug "stopped working." It reflects that the drug was doing the work, and without it, the underlying biology resumes. Phase 3 TRIUMPH trial data on long-term discontinuation effects are still emerging as of 2026.

"Retatrutide withdrawal" is a misnomer. The drug does not cause chemical dependence. Effects diminish because the drug clears, not because the body becomes dependent on it. If you're planning to stop, talk to your doctor first.

Steady State: When Does Retatrutide Start Working at Full Effect?

Steady state is the point where the amount of drug absorbed with each weekly injection equals the amount cleared between doses. At steady state, plasma levels stop climbing and stabilize at a consistent range. For retatrutide, this takes 4 to 5 weeks of weekly dosing at a given dose level.

This is not arbitrary. It takes 4 to 5 half-lives for a drug to reach steady state, regardless of the compound. With a 6-day half-life, 4 half-lives = 24 days (roughly 3.5 weeks) and 5 half-lives = 30 days (roughly 4.5 weeks). The Phase 2 trial titration design, which held each dose for 4 weeks before escalating, was calibrated to let each dose reach steady state before increasing, not just for tolerability, but for pharmacokinetic completeness (Jastreboff et al., 2023).

Why Steady State Matters for Dosing Decisions

Escalating before steady state means stacking doses on top of drug levels that are still rising. The result is an unpredictable peak concentration at the new dose. This is not necessarily dangerous, but it makes it harder to attribute side effects or appetite changes to a specific dose level. The 4-week hold at each step gives the drug time to plateau before adding more.

This also means that full appetite suppression and metabolic effects at any given dose take 4 to 5 weeks to manifest. Judging a dose's effectiveness before steady state leads to premature escalation. If you are on 4mg and wondering whether it is "working," the answer is: it depends when you started that dose. Before week 4 or 5, you may not be seeing its full effect. See the retatrutide dosing schedule for the week-by-week calendar.

Steady State Timeline by Dose Level

These timelines follow the lexicon standard titration (2mg to 4mg to 8mg to 12mg, every 4 weeks) combined with the 4-to-5-week steady-state rule. Your doctor may adjust the pace based on tolerability. See the retatrutide dosage chart for the full titration arc.

Retatrutide Half-Life vs Tirzepatide and Semaglutide

A common question: does the half-life difference between retatrutide, tirzepatide, and semaglutide actually matter? For dosing frequency, no. All three sit in the same pharmacokinetic tier (5 to 7 days) and all three use once-weekly subcutaneous injection. None requires a different schedule because of its specific half-life within that band.

The difference matters more for switching protocols and surgical washout planning. Tirzepatide at 5 days clears somewhat faster than semaglutide at 7 days, with retatrutide's 6-day half-life sitting between them. These figures are all cross-study, no head-to-head pharmacokinetic trial has compared these three agents directly.

For a detailed clinical comparison of mechanisms, weight loss outcomes, and FDA status, see the retatrutide vs tirzepatide comparison guide.

How to Use the Half-Life When Planning Your Dosing Schedule

The 6-day half-life has practical implications for three common scenarios: choosing an injection day, handling a missed dose, and planning for procedures.

Injection day choice. With a 6-day half-life, which day of the week you inject matters far less than doing it consistently. Seven days after a dose, around 44% of that dose's peak remains, and accumulation across weekly doses keeps steady-state levels high enough to stay pharmacologically active throughout the week. Pick a day that fits your routine and stick to it.

Missed dose. If you miss an injection and catch it within about 3 days of the missed date, take it and resume your normal weekly schedule from there. If more than 3 to 4 days have passed (you're approaching the next scheduled date anyway), skip the missed dose and resume normally. Never double-dose to compensate. If you're unsure, your doctor can give guidance specific to your protocol.

Before procedures. Retatrutide slows gastric emptying, and some anesthesiologists ask GLP-1 class users to hold their medication before general anesthesia. A full washout takes roughly 4 to 5 weeks given the 30-day clearance window. Your surgical team will set the specific hold period.

Does the Half-Life Affect Microdosing Protocols?

Split-dosing (taking a weekly dose in two or more smaller sub-weekly injections) changes the trough-to-peak ratio and can soften side effects at higher dose levels. The 6-day half-life makes this work differently than it would with a shorter-acting compound. But it also shifts the pharmacokinetics in ways the standard titration wasn't designed for. Full coverage of protocols and rationale lives in the microdosing retatrutide guide.